二季度,创新药行业持续走强。尽管受到关税、特朗普希望降低药价等多次扰动,但是创新药行业依然持续上涨。创新药行业年初以来的涨幅大幅度超越同类型的风险资产AI板块、机器人板块的涨幅,引发市场的高度关注。7月18日,持续看好创新药的周思聪管理的产品——平安医疗健康混合型证券投资基金发布二季报,该产品上半年取得57.41%的亮眼业绩。值得一提的是,该产品在周思聪的管理下,净值于近日突破此前2021年的...
Source Link二季度,创新药行业持续走强。尽管受到关税、特朗普希望降低药价等多次扰动,但是创新药行业依然持续上涨。创新药行业年初以来的涨幅大幅度超越同类型的风险资产AI板块、机器人板块的涨幅,引发市场的高度关注。7月18日,持续看好创新药的周思聪管理的产品——平安医疗健康混合型证券投资基金发布二季报,该产品上半年取得57.41%的亮眼业绩。值得一提的是,该产品在周思聪的管理下,净值于近日突破此前2021年的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.